CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
EPAX 1050TGdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00211159
NCT00211159N/ACompleted
CompareCT.gov

Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-blind Trial

Karolinska University Hospital·interventional·Posted Sep 21, 2005·Updated Jul 31, 2017

In Brief

A clinical study evaluating EPAX 1050TG for Alzheimer's Disease. Completed, across 1 site.

Detailed Summary

Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesSweden
Collaborators--

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 21, 2005
Enrollment StartDec 1, 2000
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

EPAX 1050TGdrug